At the ASCO 2019 annual meeting, Janice Mehnert discusses GITR as an emerging novel checkpoint in immunotherapy as well as sharing the findings from the recent study investigating the compound MK-4166 (NCT02132754) and considering the next steps in its clinical development.
Questions
1. What are the limitations of current immunotherapies in the treatment of solid tumours? (0:04)
2. What is the rationale for targeting glucocorticoid-induced tumour necrosis factor receptor (GITR)? (0:43)
3. What were the efficacy and safety findings of the recent study investigating MK-4166 as monotherapy or with pembrolizumab in patients with advanced solid tumours? (1:40)
4. What will be the next step in the clinical development of MK-4166? (2:39)
5. What other costimulatory receptors appear to be promising therapeutic targets? (3:23)
Speaker disclosure: Janice Mehnert has acted as a consultant for Merck & Co and participated in advisory boards for BMS, Reserit, Merck, Incyte and AstraZeneca.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
